Recombinant Human Plasma Phospholipid Transfer Protein (PLTP) to Prevent Bacterial Growth and to Treat Sepsis

Overview

Journal Sci Rep

Specialty Science

Date 2017 Jun 10

PMID 28596518

Citations 22

Authors

Valerie Deckert

Stephanie Lemaire

Pierre-Jean Ripoll

Jean-Paul Pais de Barros

Jerome Labbe

Caroline Chabert-Le Borgne

Veronique Turquois

Guillaume Maquart

Delphine Larose

Nicolas Desroche

Franck Menetrier

Naig Le Guern

Lorene J Lebrun

Catherine Desrumaux

Thomas Gautier

Jacques Grober

Charles Thomas

David Masson

Louis-Marie Houdebine

Laurent Lagrost

Affiliations

Soon will be listed here.

Abstract

Although plasma phospholipid transfer protein (PLTP) has been mainly studied in the context of atherosclerosis, it shares homology with proteins involved in innate immunity. Here, we produced active recombinant human PLTP (rhPLTP) in the milk of new lines of transgenic rabbits. We successfully used rhPLTP as an exogenous therapeutic protein to treat endotoxemia and sepsis. In mouse models with injections of purified lipopolysaccharides or with polymicrobial infection, we demonstrated that rhPLTP prevented bacterial growth and detoxified LPS. In further support of the antimicrobial effect of PLTP, PLTP-knocked out mice were found to be less able than wild-type mice to fight against sepsis. To our knowledge, the production of rhPLTP to counter infection and to reduce endotoxemia and its harmful consequences is reported here for the first time. This paves the way for a novel strategy to satisfy long-felt, but unmet needs to prevent and treat sepsis.

Citing Articles

The role of phospholipid transfer protein in sepsis-associated acute kidney injury.

Jiang W, Song L, Gong W, Li X, Shi K, Li L Crit Care. 2025; 29(1):33.

PMID: 39833975 PMC: 11745024. DOI: 10.1186/s13054-025-05253-6.

Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarction.

Nguyen M, Putot A, Masson D, Cottin Y, Gautier T, Tribouillard L Front Cardiovasc Med. 2024; 11:1419001.

PMID: 38984349 PMC: 11232875. DOI: 10.3389/fcvm.2024.1419001.

Phospholipid transfer protein ameliorates sepsis-induced cardiac dysfunction through NLRP3 inflammasome inhibition.

Wang J, Hou J, Peng C Open Med (Wars). 2024; 19(1):20240915.

PMID: 38584827 PMC: 10996989. DOI: 10.1515/med-2024-0915.

Cytokine dysregulation despite immunoglobulin replacement therapy in common variable immunodeficiency (CVID).

Poto R, Pecoraro A, Ferrara A, Punziano A, Lagnese G, Messuri C Front Immunol. 2023; 14:1257398.

PMID: 37841257 PMC: 10568625. DOI: 10.3389/fimmu.2023.1257398.

Endotoxemia in Acute Heart Failure and Cardiogenic Shock: Evidence, Mechanisms and Therapeutic Options.

Nguyen M, Gautier T, Masson D, Bouhemad B, Guinot P J Clin Med. 2023; 12(7).

PMID: 37048662 PMC: 10094881. DOI: 10.3390/jcm12072579.

References

Brinster R, Chen H, Trumbauer M, Yagle M, Palmiter R . Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A. 1985; 82(13):4438-42. PMC: 391116. DOI: 10.1073/pnas.82.13.4438. View

Huuskonen J, Olkkonen V, Jauhiainen M, Sareneva T, Somerharju P, Ehnholm C . Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer. Biochim Biophys Acta. 1998; 1391(2):181-92. DOI: 10.1016/s0005-2760(98)00008-3. View

Attal J, Theron M, Taboit F, Cajero-Juarez M, Kann G, Bolifraud P . The RU5 ('R') region from human leukaemia viruses (HTLV-1) contains an internal ribosome entry site (IRES)-like sequence. FEBS Lett. 1996; 392(3):220-4. DOI: 10.1016/0014-5793(96)00815-0. View

Fink M, Warren H . Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 2014; 13(10):741-58. DOI: 10.1038/nrd4368. View

Fan J, Watanabe T . Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther. 2003; 99(3):261-82. DOI: 10.1016/s0163-7258(03)00069-x. View

Rittirsch D, Huber-Lang M, Flierl M, Ward P . Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009; 4(1):31-6. PMC: 2754226. DOI: 10.1038/nprot.2008.214. View

Albers J, Day J, Wolfbauer G, Kennedy H, Vuletic S, Cheung M . Impact of site-specific N-glycosylation on cellular secretion, activity and specific activity of the plasma phospholipid transfer protein. Biochim Biophys Acta. 2011; 1814(7):908-11. PMC: 3112057. DOI: 10.1016/j.bbapap.2011.04.004. View

Van den Hout J, Reuser A, De Klerk J, Arts W, Smeitink J, van der Ploeg A . Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis. 2001; 24(2):266-74. DOI: 10.1023/a:1010383421286. View

Lehmann C, Sharawi N, Al-Banna N, Corbett N, Kuethe J, Caldwell C . Novel approaches to the development of anti-sepsis drugs. Expert Opin Drug Discov. 2014; 9(5):523-31. DOI: 10.1517/17460441.2014.905538. View

10.

Wang Y, Zhao S, Bai L, Fan J, Liu E . Expression systems and species used for transgenic animal bioreactors. Biomed Res Int. 2013; 2013:580463. PMC: 3613084. DOI: 10.1155/2013/580463. View

11.

Gautier T, Klein A, Deckert V, Desrumaux C, Ogier N, Sberna A . Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem. 2008; 283(27):18702-10. DOI: 10.1074/jbc.M802802200. View

12.

Klein A, Deckert V, Schneider M, Dutrillaux F, Hammann A, Athias A . Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: relevance in phospholipid transfer protein-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26(9):2160-7. DOI: 10.1161/01.ATV.0000235699.98024.11. View

13.

Jiang X, Bruce C, Mar J, Lin M, Ji Y, Francone O . Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999; 103(6):907-14. PMC: 408146. DOI: 10.1172/JCI5578. View

14.

Ooi C, Weiss J, Elsbach P, Frangione B, Mannion B . A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem. 1987; 262(31):14891-4. View

15.

Levels J, Marquart J, Abraham P, van den Ende A, Molhuizen H, van Deventer S . Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun. 2005; 73(4):2321-6. PMC: 1087464. DOI: 10.1128/IAI.73.4.2321-2326.2005. View

16.

Merx M, Liehn E, Janssens U, Lutticken R, Schrader J, Hanrath P . HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004; 109(21):2560-5. DOI: 10.1161/01.CIR.0000129774.09737.5B. View

17.

Riedl M . Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. Clin Drug Investig. 2015; 35(7):407-17. PMC: 4488495. DOI: 10.1007/s40261-015-0300-z. View

18.

Recillas-Targa F, Pikaart M, Burgess-Beusse B, Bell A, Litt M, West A . Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci U S A. 2002; 99(10):6883-8. PMC: 124498. DOI: 10.1073/pnas.102179399. View

19.

Horwitz A, Williams R, Liu P, NADELL R . Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the gram-positive bacteria Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 1999; 43(9):2314-6. PMC: 89470. DOI: 10.1128/AAC.43.9.2314. View

20.

Domingues M, Silva P, Franquelim H, Carvalho F, Castanho M, Santos N . Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria. Nanomedicine. 2013; 10(3):543-51. DOI: 10.1016/j.nano.2013.11.002. View